Preview Newsletter
XARELTO Media Monitoring – Week of 7-15-16
-
Announcement Of Bellwether Trial Dates For Xarelto Lawsuit Cases In MDL
Jul 8, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com offers insight on the latest court announcement regarding the lawsuits contained in the multidistrict litigation (MDL) 2592 against Xarelto and its manufacturers, Janssen Pharmaceuticals and Bayer AG. The court ordered that four cases be selected for bellwether trials. Dates for all four trials have been announced. The first two will be held in the Eastern District of Louisiana on February 6th and March 13th of 2017. The third and fourth trials will be heard in a Texas court on April 24th and May 30th of 2017, respectively. -
Studies Link Risk Of Hemorrhage To Drug Supporting Claims Made By Xarelto Lawsuit Plaintiffs
Jul 8, 2016 | TheProductLawyers.com
By Banville Law
July 08, 2016 – /PressAdvantage/ – TheProductLawyers.com reports on several studies which appear to link the use of Xarelto and the risk of hemorrhages which would support the claims of plaintiffs in the multi-district litigation (MDL) 2592 against Xarelto and its manufacturers—Janssen Pharmaceuticals and Bayer AG. These studies found a heightened potential for stomach and eye bleeding events following a switch from traditional blood thinner medications to Xarelto. -
Dru_gs Claim Provide Justice and Compensation for Xarelto Side Effects
Jul 11, 2016 | wesrch.com
By Drugs Claim
Blood-thinner Xarelto (also known as Rivaroxaban) cause many health complications and emotional distress for patients treated with this harmful medicine. Patient needs to immediately consult to doctors to cure Side Effects of Xarelto and get the new happier and healthy life once again. Patient’s report shows that unsafe medicine used to treat strokes and prevent blood clotting in veins results in such injurious complications that are not recovered by any antidote. -
Xarelto litigants anticipate selection and start of federal bellwether trials in 2017
Jul 11, 2016 | Penn Records
By Nicholas Malfitano
NEW ORLEANS – As more and more cases continue to be filed by plaintiffs and their counsel against the manufacturers of the blood thinner Xarelto, these litigants are looking towards the horizon of bellwether cases in this matter to be heard next year. -
Xarelto Lawsuits Now Over 5000 and Continuing to Grow
Jul 11, 2016 | Noodls
By Parker Waichman LLP
Barely two months ago, the multidistrict litigation Xarelto lawsuits numbered about 4,500. Today, there are over 5,381 cases pending in U.S. District Court for the Eastern District of Louisiana. For some time, experts have maintained that the way that Xarelto, along with Pradaxa, were brought to market, but requiring less monitoring and having no available antidote, could result in heavy litigation. -
Xarelto litigants anticipate selection and start of federal bellwether trials in 2017
Jul 11, 2016 | Penn Record
By Nicholas Malfitano
NEW ORLEANS – As more and more cases continue to be filed by plaintiffs and their counsel against the manufacturers of the blood thinner Xarelto, these litigants are looking towards the horizon of bellwether cases in this matter to be heard next year. -
Research Lends Weight To Xarelto Lawsuit Claims
Jul 11, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com announces that recent research may support claims against Xarelto and its manufacturers—Bayer AG and Janssen Pharmaceuticals, a division of Johnson & Johnson. Links between the use of Xarelto by those who have previously relied on traditional blood thinner medications indicate that an elevated risk of eye and stomach bleeding events may exist. -
Studies Could Substantiate Claims In Xarelto Lawsuit Cases
Jul 11, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com offers insight on recent research that may lend credibility to the claims against Xarelto and its manufacturers—Janssen Pharmaceuticals (a division of Johnson & Johnson) and Bayer AG. The observations of researchers appear to substantiate Xarelto's potential association with eye and gastrointestinal bleeding events, which would aid the case against the new-generation anticoagulant. -
Xarelto Earns Another Dubious Distinction From ISMP: Most Serious Injuries of All Drugs in 2015
Jul 12, 2016 | XareltoLawsuit.com
By Miller Legal LLP
The blood thinner Xarelto (rivaroxaban) has often been labeled by some as a dangerous drug because of the risks of internal bleeding, strokes, blood clots, wound infections and other side effects with which it has been associated. In fact, the Institute for Safe Medication Practices (ISMP), a noted consumer advocacy group, has repeatedly drawn attention to Xarelto risks through their QuarterWatch reports and has even suggested that the risks of Xarelto may outweigh the benefits. Now, Xarelto is again given extra attention in the group’s most recent QuarterWatch report, in which they state that Xarelto was associated with more serious injuries than any other drug they monitored in 2015. -
Judge Fallon Issues Case Management Orders For MDL Of Xarelto Lawsuit Cases Regarding Bellwether Trials
Jul 12, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com offers insight on the latest developments in the mass litigation against Xarelto and it's manufacturers—Janssen Pharmaceuticals, a division of Johnson & Johnson, and Bayer AG. Late in 2015, the U.S. Judicial Panel on Multidistrict Litigation agreed to combine 2,800 federally-filed lawsuits against the drug companies on the basis of common allegations. They appointed Judge Eldon Fallon to preside over the MDL in the Eastern District of Louisiana. -
CardioBrief: Warfarin Monitoring System Cited in Controversy Withdrawn
Jul 13, 2016 | Larry Husten
By MedPage Today
The Alere INRatio and INRatio2 PT/INR Monitoring System are being pulled from the market. Alere, the manufacturer of the devices, which are used by people taking warfarin (Coumadin) to monitor their INR, said that the action follows a "collaborative process" with the FDA. -
Vermont Man Dies From Uncontrollable Bleed, Daughter Files Xarelto Lawsuit
Jul 13, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com outlines the details of a new development in Vermont, where a local woman has filed a lawsuit against the manufacturers of the anticoagulant, Xarelto, alleging that the drug caused her father’s uncontrollable bleeding incident and resulting death. The manufacturers of Xarelto are Bayer AG and Janssen Pharmaceuticals, which is a subsidiary of Johnson & Johnson corporation. The lawsuit was filed on July 25th, 2014 in a federal court in Vermont, and was filed under No. 2:14-cv-00158-CR by the victim's daughter on behalf of her father. -
Almost 6000 Lawsuits Consolidated in Xarelto Litigation
Jul 14, 2016 | LawyersandSettlements.com
By Heidi Turner
New Orleans, LA -- With almost 6,000 Xarelto lawsuits consolidated for pretrial proceedings, and more being regularly filed, plaintiffs await the day that bellwether trials will be heard. Those bellwether cases will set the tone for future Xarelto litigation, and will show both sides what the experts have to say about Xarelto side effects. -
Study Results Show Support Xarelto Lawsuit Plaintiff Allegations, Linking Drug To Bleeding Episodes
Jul 14, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the results of several recently concluded studies, that seem to support Xarelto lawsuit plaintiff’s allegations linking the anticoagulant to several dangerous, unexpected bleeding episodes. A multitude of Xarelto lawsuit plaintiffs have alleged that the blood-thinning drug can cause serious and even fatal uncontrollable bleeding episodes, which makes these new findings even more important to the rapidly approaching Xarelto bellwether court proceedings. -
Honorable U.S. District Judge Eldon E. Fallon Sets Xarelto Lawsuit Bellwether Court Proceedings For Early 2017
Jul 14, 2016 | The ProductLawyers.com
By Banville Law
TheProductLawyers.com reports on an update in the on-going Xarelto multidistrict litigation in Louisiana. MDL No. 2592 currently has 2800+ cases that are being overseen by U.S. District Judge Eldon E. Fallon in the Eastern District of Louisiana. The first two bellwether trials will be held on February 6th and March 13th of 2017. In the following months, the remaining two bellwether trials will be heard on April 24th and May 30th respectively. -
Xarelto Lawsuit Plaintiffs Await Trial, As Similarities To Previous Pradaxa Lawsuits Continue To Emerge
Jul 14, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com recently outlined the sizable similarities between Xarelto and Pradaxa lawsuits, which have provided some hope to Xarelto lawsuit plaintiffs as they await future court dates. Xarelto lawsuit cases are currently still increasing in number, and cases have been consolidated in both Louisiana and Pennsylvania. The U.S. Judicial Panel on Multidistrict Litigation created MDL No. 2592, which was appointed to U.S. District Judge Eldon E. Fallon of Eastern Louisiana, and contains over 2,800 cases. -
Xarelto Lawsuit Filed By Texas Couple, Alleging Manufacturers Exhibited Negligence Through Inadequate Warnings
Jul 14, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on another lawsuit that has been filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals, a division of Johnson & Johnson. The lawsuit was filed against the manufacturers, in relation to Xarelto, which is an anticoagulant drug that has been a popular blood thinner on the market for nearly 5 years. Since hitting the market, thousands of similar lawsuits have been filed nationwide. -
Xarelto Lawsuit: In Favor of Victims
Jul 9, 2016 | WeaselReader.org
By Weasel
Modern medical science is a boon for the patients suffering from various ailments. But these drugs, having been made of chemicals, also lead to some side effects, many of which can be of a serious nature. One such drug is Xarelto, an anticoagulant prescribed by physicians to their patients suffering from hypertension and cardiovascular diseases. There is no doubt that Xarelto does its work well and keeps the blood of the user thin to prevent any chances of thrombosis. But it also causes some side effects, the most serious of them being internal bleeding because of injuries. What is baffling to know is the fact that this uncontrolled bleeding can prove to be fatal as there is no known antidote for this bleeding. -
Plaintiffs Oppose Proposed $11.75M Pelvic Mesh Settlement
Jul 11, 2016 | Top Class Actions
By Amanda Antell
Three dozen women are objecting to a proposed $11.75 million pelvic mesh settlement, stating they want proof that the payout would be greater than if the manufacturing company liquidated itself. -
Eliquis Wrongful Death Lawsuit Says Blood Thinner Unsafe
Jul 11, 2016 | Top Class Actions
By Ashley Milano
Pfizer and Bristol-Myers Squibb are facing an Eliquis wrongful death lawsuit, alleging that their blood thinner Eliquis (also known as apixaban) is dangerous and should not be prescribed. -
Xarelto Lawsuit Says Drug Makers Failed to Warn About Bleeding
Jul 14, 2016 | Top Class Actions
By Paul Tassin
A man from Michigan has filed a Xarelto lawsuit blaming the drug’s manufacturers for his episodes of bleeding and need for additional medical care. -
Vaginal Mesh Implants Now Under Strict FDA Rules
Jul 14, 2016 | Top Class Actions
By Kim Gale
In January, the FDA issued two final orders to strengthen the data requirements for vaginal mesh implants that are used to treat pelvic organ prolapse. -
Xarelto Update: Trials May Begin in 2017
Jul 14, 2016 | FindLaw
By Christopher Coble
For people with irregular heart rhythm, hypertension, or another valvular heart condition, blood thinners can help prevent dangerous and potentially deadly blood clots. But as with any medication, there are risks of side effects. -
What Are the Side Effects of Xarelto?
Jul 15, 2016 | Top Class Actions
By Ashley Milano
Lawsuits against Xarelto’s manufacturers are being filed across the country. The lawsuits allege that side effects of Xarelto caused severe bleeding, injuries and deaths, and that patients and doctors were not adequately warned about the risks of internal bleeding from Xarelto.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
-
Announcement Of Bellwether Trial Dates For Xarelto Lawsuit Cases In MDL
Jul 8, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com offers insight on the latest court announcement regarding the lawsuits contained in the multidistrict litigation (MDL) 2592 against Xarelto and its manufacturers, Janssen Pharmaceuticals and Bayer AG. The court ordered that four cases be selected for bellwether trials. Dates for all four trials have been announced. The first two will be held in the Eastern District of Louisiana on February 6th and March 13th of 2017. The third and fourth trials will be heard in a Texas court on April 24th and May 30th of 2017, respectively.
Since the FDA granted Xarelto approval in 2011, the opinion that it is the most dangerous anticoagulant on the market has grown. To date, more than 2,800 federally-filed lawsuits against the drug and its manufacturers have been combined into MDL 2592. A majority of claims include the belief that taking the new-generation anticoagulant exposes individuals to an elevated risk of clots, strokes, catastrophic bleeding events that include gastrointestinal and eye hemorrhages and other serious complications. Another common allegation among the plaintiffs is that of negligence on the part of the manufacturers to appropriately advise the public of potential risks associated with Xarelto.
The bellwether trials are intended to assist all parties in better understanding potential jury reaction to certain testimony or evidence present in future trials. This will assist attorneys in crafting arguments and selecting data, further streamlining the processes of justice. As MDL 2592 approaches bellwether trials, plaintiffs anticipate that additional federal cases will be added to their numbers.
"Our lawsuits allege that the manufacturers failed to warn our clients about the severe side effects that our client's suffered from while taking the drug," said attorney Laurence Banville, a contributor to the Xarelto litigation updates on TheProductLawyers.com. "We are speaking with families who have had brain bleeds, gastrointestinal bleeds, vaginal bleeding, and bleeding from trauma where hospitalization and extreme measures were taken by medical staff to help save the patient's life," Banville continued. "We look forward to fighting for the rights of our clients and pursuing just compensation for the injuries and hospitalization."
http://www.digitaljournal.com/pr/3000135#ixzz4E71sglhH
-
Studies Link Risk Of Hemorrhage To Drug Supporting Claims Made By Xarelto Lawsuit Plaintiffs
Jul 8, 2016 | TheProductLawyers.com
By Banville Law
July 08, 2016 – /PressAdvantage/ – TheProductLawyers.com reports on several studies which appear to link the use of Xarelto and the risk of hemorrhages which would support the claims of plaintiffs in the multi-district litigation (MDL) 2592 against Xarelto and its manufacturers—Janssen Pharmaceuticals and Bayer AG. These studies found a heightened potential for stomach and eye bleeding events following a switch from traditional blood thinner medications to Xarelto.
The U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated more than 2,800 federally-filed suits to form MDL 2592, in which plaintiffs support a common allegation of increased risk of catastrophic bleeding episodes and resultant injuries. The cases will be tried in the Eastern District of Louisiana by Judge Eldon Fallon. Another mass tort program comprised of more than 550 lawsuits has been consolidated by the Philadelphia Court of Common Pleas.
Drs. Judy H. Hun and John C. Hwang conducted a study that has highlighted the potential risks associated with the use of Xarelto. At first, after reviewing the mounting complaints against the drug, the doctors conducted a preliminary study among patients in their own practice. Focusing on those aged 70 to 80 who had transitioned from other, traditional blood thinners to the new-generation anticoagulant, they observed certain commonalities. Those who had a history of traditional blood thinner use and who switched the new-generation blood thinner were more likely to suffer from vitreous hemorrhages. Vitreous hemorrhages specifically occur between the lens and retina of the eye.
In cases of this type of bleeding, the doctors noted that it “occurred shortly after rivaroxaban (Xarelto) was initiated.” There is a potential link between the bleeding events and the decision to transition to Xarelto, which the Hwang and Hun hope will instill a note of caution in physicians planning to prescribe it to patients with existing anticoagulant regimens.
However, another study published in the April 2015 edition of the British Medical Journal (BMJ) may further serve to reinforce a cautious approach to Xarelto. Reviewing more than 46,000 patients currently using anticoagulants including warfarin and Xarelto, the researchers were unable to discount a twofold increase in the risk of a stomach (gastrointestinal) hemorrhage.
http://www.wave3.com/story/32405640/studies-link-risk-of-hemorrhage-to-drug-supporting-claims-made-by-xarelto-lawsuit-plaintiffs
-
Dru_gs Claim Provide Justice and Compensation for Xarelto Side Effects
Jul 11, 2016 | wesrch.com
By Drugs Claim
Blood-thinner Xarelto (also known as Rivaroxaban) cause many health complications and emotional distress for patients treated with this harmful medicine. Patient needs to immediately consult to doctors to cure Side Effects of Xarelto and get the new happier and healthy life once again. Patient’s report shows that unsafe medicine used to treat strokes and prevent blood clotting in veins results in such injurious complications that are not recovered by any antidote.
Manufactured by Johnson & Johnson’s Janssen Pharmaceutical and Bayer, Xarelto side effects lead to hospitalization and patient’s death also. FDA approved this medicine for the treatment of pulmonary embolism, deep vein thrombosis and patient who has undergone hip or knee replacement surgery.
Negligence of Bayer for not warning the health community, physicians and patients about the side effects have destroy the life of many people. Intraparenchymal hemorrhages, brain bleeds or Parenchymal are the life-threatening health conditions that can never be cured. Uncontrolled bleeding is Xarelto’s serious side effect that is suffered by numbers of people. The major body organs such as kidneys, brain or lungs lose their functionality once the bleeding starts occurring as it interrupt the blood flow.
Xarelto Lawsuit Settlement provides one of the best solutions for the injured patient to get legal security, justice and remuneration for all the losses and pain. Plaintiffs can take the manufacturers in the court for their carelessness and damage, people suffered due to unsafe medicine. Dru_gs Claim helps to choose the skilled attorney who study their case individually and represent it in effective way by following the correct legal step.
So far, the group of lawyers has filed over thousands of lawsuits in the court for people suffering from emotional and health complications because of manufacturer’s fault. People injured with Xarelto side effects and seeking financial help can easily file a claim without burning a hole in pocket. No attorney fee is charged before the settlement and providing the deserved compensation to clients.
Dru_gs Claim team provides all the necessary information and useful solutions for problems occur due to dangerous medicine. The company helps plaintiffs to consult experienced and knowledgeable lawyers who offer free case evaluation.
Xarelto Lawsuit Claims can be filed for several reasons:Taking Janssen Pharmaceuticals and Bayer to court for releasing unsafe blood thinnerEmotional distressLost wages, emergency hospital visits and all the financial hardship caused due to Xarelto complicationsBurden of funeral expenses
A person is entitled for lawsuit only if they are affected by the side effects of real brand of Xarelto. They get right to file claims within limited time duration i.e. statute of limitations. So, find the right attorney and get legal solution of complications.
http://www.wesrch.com/business/paper-details/press-paper-BU187Q2NFNKAL-dru-gs-claim-provide-justice-and-compensation-for-xarelto-side-effects
-
Xarelto litigants anticipate selection and start of federal bellwether trials in 2017
Jul 11, 2016 | Penn Records
By Nicholas Malfitano
NEW ORLEANS – As more and more cases continue to be filed by plaintiffs and their counsel against the manufacturers of the blood thinner Xarelto, these litigants are looking towards the horizon of bellwether cases in this matter to be heard next year.
Per Judge Eldon E. Fallon of the U.S. District Court for the Eastern District of Louisiana, bellwether trials in the multi-district litigation (MDL) revolving around Xarelto will begin in early 2017, with the selection and scheduling process currently underway.
The federal Xarelto MDL is listed as Case No. 2592, consolidating individual actions filed against Xarelto’s manufacturers, Bayer and Janssen Pharmaceuticals.
Litigants charge Bayer and Janssen failed to properly warn patients that Xarelto use presented increased risks for cranial and gastrointestinal bleeding when taken once daily. Risks which the plaintiffs say, allegedly, would be greatly decreased if the drug was taken twice daily and monitored properly.
Before the main cases reach federal courtrooms, 40 bellwether cases are being selected as a result of a January order from Fallon. These bellwether actions will enable litigants and counsel to see how jury panels react to evidence presented.
“The problem in the past with selecting bellwether cases is that we didn’t drill down on the numbers of cases in order to decide what a good bellwether case is. It was a little bit random,” Fallon said in a January status conference. “So what we are trying to do now is to pick 40 cases. Hopefully, these 40 cases mimic the census of the entire litigation.”
At this point, the first four bellwether cases have been slated for hearings. Respectively, the first and second bellwether cases are scheduled to be heard on Feb. 6 and March 13, 2017, in the U.S. District Court for the Eastern District of Louisiana.
Likewise, the third and fourth bellwether cases will be heard on April 24 and May 30, 2017, in federal district courts yet to be specified in Mississippi and Texas, respectively. However, the specific cases for these initial four bellwether dates have yet to be selected and the hearing locations for the latter two are subject to change, per the MDL’s Case Management Order No. 2.
Liaison counsel for the plaintiffs in this MDL are Gerald Edward Meunier of Gainsburgh Benjamin David Meunier & Warshauer, and Leonard A. Davis of Herman Herman & Katz, both based in New Orleans.
Defense liaison counsel in the MDL is James B. Irwin of Irwin Fritchie Urquhart & Moore, also of New Orleans.
In addition to a grouping of Xarelto claims being processed in a Louisiana federal court, more than 800 lawsuits – most from out-of-state plaintiffs – will be handled in Philadelphia’s Complex Litigation Center. The CLC has several mass tort programs, including cases over asbestos and Risperdal, and the percentage of claims belonging to out-of-state plaintiffs is typically in the high 80s.
But how may the cases in the federal Xarelto MDL affect those filed in Philadelphia?
Philadelphia-based attorney Max Kennerly of Kennerly Loutey clarified that while state and federal courts can cooperate on subjects such as scheduling and assistance in settlement talks, the courts may diverge when it comes to key legal orders, such as rulings on expert witnesses and summary judgment motions.
“It’s common to see state and federal courts reach differing rulings on these issues, primarily because the courts follow different precedent and different rules of evidence,” Kennerly said.
Providing an example of this contrast, Kennerly said the Daubertstandard would govern the admissibility of expert witness testimony in the federal Xarelto MDL, while the Frye standard would be used as a similar guideline for cases handled in state court, such as those which will be litigated in Philadelphia next year.
The Daubert standard determines if expert testimony is based on “scientifically-valid” criteria and methodology, and can be properly applied to the subject at issue – whereas the Frye standard determines if the method by which a certain piece of evidence is obtained is “generally accepted” by experts in its related field.
“Although there are some areas of law in which one court’s ruling could be very persuasive to another court – such as when the courts have to interpret the law of a particular state – the specifics of each bellwether case are often so different that there’s not much that a court could draw upon in deciding issues raised by a different bellwether,” Kennerly said.
“Although there’s some superficial appeal to the notion that the state and federal courts would bend their rulings to create consistency, the bigger and more important concerns come from federalism and judicial independence. A judge in one court might look to see how another court handled a particular issue, but when it comes to making a decision, the decision is theirs and theirs alone,” Kennerly added.
On the question of why some Xarelto cases are filed in federal court versus state court, Kennerly explained there's no one factor which decides the issue and the claims involved are rarely different.
“In both circumstances, the claims available are usually determined by the law of the state in which the plaintiff resides,” Kennerly said. “Many times, plaintiffs' lawyers will choose the forum with which they are more familiar because they will be better able to follow the overall status of the litigation and, correspondingly, be better able to advise their client.”
With respect to the federal court system, Kennerly spoke to the perception of it being considered the “most convenient and familiar venue” for many lawyers, due to the uniformity of the rules of civil procedure, accessibility of local rules for each court and ease in monitoring docket developments through the ECF/PACER system. Plus, Kennerly noted, for out-of-state lawyers, there is no need to find local counsel to file the case in a federal MDL.
Kennerly indicated results of bellwether cases are significant to future litigation.
“If the bellwethers in one court end up consistently being dismissed or losing, while the bellwethers in another court consistently produce substantial verdicts, that can play a role in settlement discussions,” Kennerly said.
Stanley Thompson, Director of the CLC, said he was “not sure at this juncture” how results from the Xarelto MDL cases could affect cases filed in Philadelphia.
“Hopefully, any verdicts rendered or resolutions reached with respect to the MDL cases will help with narrowing of issues and establishing the value of these cases, generally, which could lead to enhanced management and resolution of matters pending in the Philadelphia program,” Thompson said.
Thompson stated Philadelphia courts could learn more about the Xarelto litigation based on the MDL proceedings, which would be helpful, but those case outcomes may not necessarily affect how things proceed in Philadelphia.
“We usually meet with counsel monthly to address important, relevant issues affecting the litigants and the Court, from pleadings to discovery to trial scheduling. We do work with MDL courts when practicable,” Thompson commented. “However, we proceed based on issues affecting our program and we employ procedures, protocols and processes which best allow us to meet our objectives, including timely and efficient disposition of cases.”
As of this week, about 860 cases had been filed in the Xarelto program at the CLC, overseen by Judge Arnold New. The first cases there were filed in February 2014, and previously-reported indications point toward a bellwether case being heard in a Philadelphia courtroom, at the earliest, in the summer of 2017.
http://pennrecord.com/stories/510940974-xarelto-litigants-anticipate-selection-and-start-of-federal-bellwether-trials-in-2017
-
Xarelto Lawsuits Now Over 5000 and Continuing to Grow
Jul 11, 2016 | Noodls
By Parker Waichman LLP
Barely two months ago, the multidistrict litigation Xarelto lawsuits numbered about 4,500. Today, there are over 5,381 cases pending in U.S. District Court for the Eastern District of Louisiana. For some time, experts have maintained that the way that Xarelto, along with Pradaxa, were brought to market, but requiring less monitoring and having no available antidote, could result in heavy litigation.
Coumadin (warfarin) the tried-and-true anticoagulant, has remained effective as a viable blood thinner for patients with atrial fibrillation or for those at risk for stroke. Stringent blood monitoring and a somewhat rigid diet is required, but an infusion of vitamin K provides an effective antidote in case of sudden bleeds, reports LawyersandSettlements.com.
Although there has always been a risk for uncontrolled bleeding with Coumadin, an emphasis on blood and diet monitoring has been effective in providing a reasonably safe status with warfarin. Like warfarin, there is also a bleed out risk for rivaroxaban (Xarelto).
One plaintiff is suing the Xarelto manufacturer on behalf of her husband who suffered a Xarelto bleed out in his brain. He had been taking Xarelto for six months for atrial fibrillation when he died. Another plaintiff is suing on behalf of her father. He had been prescribed Xarelto for only a month due to stroke risk, when he suffered a serious Xarelto bleeding issue in his brain and died, reports LawyersandSettlements.com.
Plaintiffs are alleging that not only was the Xarelto manufacturer negligent in bringing Xarelto to market without an available antidote, but that patients were not adequately advised or warned regarding the lack of a reversing agent, so long a part of the established warfarin equation.
http://www.noodls.com/view/8192BC5607E19FFD1A173D8528450A2DF897FF66
-
Xarelto litigants anticipate selection and start of federal bellwether trials in 2017
Jul 11, 2016 | Penn Record
By Nicholas Malfitano
NEW ORLEANS – As more and more cases continue to be filed by plaintiffs and their counsel against the manufacturers of the blood thinner Xarelto, these litigants are looking towards the horizon of bellwether cases in this matter to be heard next year.
Per Judge Eldon E. Fallon of the U.S. District Court for the Eastern District of Louisiana, bellwether trials in the multi-district litigation (MDL) revolving around Xarelto will begin in early 2017, with the selection and scheduling process currently underway.
The federal Xarelto MDL is listed as Case No. 2592, consolidating individual actions filed against Xarelto’s manufacturers, Bayer and Janssen Pharmaceuticals.
Litigants charge Bayer and Janssen failed to properly warn patients that Xarelto use presented increased risks for cranial and gastrointestinal bleeding when taken once daily. Risks which the plaintiffs say, allegedly, would be greatly decreased if the drug was taken twice daily and monitored properly.
Before the main cases reach federal courtrooms, 40 bellwether cases are being selected as a result of a January order from Fallon. These bellwether actions will enable litigants and counsel to see how jury panels react to evidence presented.
“The problem in the past with selecting bellwether cases is that we didn’t drill down on the numbers of cases in order to decide what a good bellwether case is. It was a little bit random,” Fallon said in a January status conference. “So what we are trying to do now is to pick 40 cases. Hopefully, these 40 cases mimic the census of the entire litigation.”
At this point, the first four bellwether cases have been slated for hearings. Respectively, the first and second bellwether cases are scheduled to be heard on Feb. 6 and March 13, 2017, in the U.S. District Court for the Eastern District of Louisiana.
Likewise, the third and fourth bellwether cases will be heard on April 24 and May 30, 2017, in federal district courts yet to be specified in Mississippi and Texas, respectively. However, the specific cases for these initial four bellwether dates have yet to be selected and the hearing locations for the latter two are subject to change, per the MDL’s Case Management Order No. 2.
Liaison counsel for the plaintiffs in this MDL are Gerald Edward Meunier of Gainsburgh Benjamin David Meunier & Warshauer, and Leonard A. Davis of Herman Herman & Katz, both based in New Orleans.
Defense liaison counsel in the MDL is James B. Irwin of Irwin Fritchie Urquhart & Moore, also of New Orleans.
In addition to a grouping of Xarelto claims being processed in a Louisiana federal court, more than 800 lawsuits – most from out-of-state plaintiffs – will be handled in Philadelphia’s Complex Litigation Center. The CLC has several mass tort programs, including cases over asbestos and Risperdal, and the percentage of claims belonging to out-of-state plaintiffs is typically in the high 80s.
But how may the cases in the federal Xarelto MDL affect those filed in Philadelphia?
Philadelphia-based attorney Max Kennerly of Kennerly Loutey clarified that while state and federal courts can cooperate on subjects such as scheduling and assistance in settlement talks, the courts may diverge when it comes to key legal orders, such as rulings on expert witnesses and summary judgment motions.
“It’s common to see state and federal courts reach differing rulings on these issues, primarily because the courts follow different precedent and different rules of evidence,” Kennerly said.
Providing an example of this contrast, Kennerly said the Daubertstandard would govern the admissibility of expert witness testimony in the federal Xarelto MDL, while the Frye standard would be used as a similar guideline for cases handled in state court, such as those which will be litigated in Philadelphia next year.
The Daubert standard determines if expert testimony is based on “scientifically-valid” criteria and methodology, and can be properly applied to the subject at issue – whereas the Frye standard determines if the method by which a certain piece of evidence is obtained is “generally accepted” by experts in its related field.
“Although there are some areas of law in which one court’s ruling could be very persuasive to another court – such as when the courts have to interpret the law of a particular state – the specifics of each bellwether case are often so different that there’s not much that a court could draw upon in deciding issues raised by a different bellwether,” Kennerly said.
“Although there’s some superficial appeal to the notion that the state and federal courts would bend their rulings to create consistency, the bigger and more important concerns come from federalism and judicial independence. A judge in one court might look to see how another court handled a particular issue, but when it comes to making a decision, the decision is theirs and theirs alone,” Kennerly added.
On the question of why some Xarelto cases are filed in federal court versus state court, Kennerly explained there's no one factor which decides the issue and the claims involved are rarely different.
“In both circumstances, the claims available are usually determined by the law of the state in which the plaintiff resides,” Kennerly said. “Many times, plaintiffs' lawyers will choose the forum with which they are more familiar because they will be better able to follow the overall status of the litigation and, correspondingly, be better able to advise their client.”
With respect to the federal court system, Kennerly spoke to the perception of it being considered the “most convenient and familiar venue” for many lawyers, due to the uniformity of the rules of civil procedure, accessibility of local rules for each court and ease in monitoring docket developments through the ECF/PACER system. Plus, Kennerly noted, for out-of-state lawyers, there is no need to find local counsel to file the case in a federal MDL.
Kennerly indicated results of bellwether cases are significant to future litigation.
“If the bellwethers in one court end up consistently being dismissed or losing, while the bellwethers in another court consistently produce substantial verdicts, that can play a role in settlement discussions,” Kennerly said.
Stanley Thompson, Director of the CLC, said he was “not sure at this juncture” how results from the Xarelto MDL cases could affect cases filed in Philadelphia.
“Hopefully, any verdicts rendered or resolutions reached with respect to the MDL cases will help with narrowing of issues and establishing the value of these cases, generally, which could lead to enhanced management and resolution of matters pending in the Philadelphia program,” Thompson said.
Thompson stated Philadelphia courts could learn more about the Xarelto litigation based on the MDL proceedings, which would be helpful, but those case outcomes may not necessarily affect how things proceed in Philadelphia.
“We usually meet with counsel monthly to address important, relevant issues affecting the litigants and the Court, from pleadings to discovery to trial scheduling. We do work with MDL courts when practicable,” Thompson commented. “However, we proceed based on issues affecting our program and we employ procedures, protocols and processes which best allow us to meet our objectives, including timely and efficient disposition of cases.”
As of this week, about 860 cases had been filed in the Xarelto program at the CLC, overseen by Judge Arnold New. The first cases there were filed in February 2014, and previously-reported indications point toward a bellwether case being heard in a Philadelphia courtroom, at the earliest, in the summer of 2017.
http://pennrecord.com/stories/510940974-xarelto-litigants-anticipate-selection-and-start-of-federal-bellwether-trials-in-2017
-
Research Lends Weight To Xarelto Lawsuit Claims
Jul 11, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com announces that recent research may support claims against Xarelto and its manufacturers—Bayer AG and Janssen Pharmaceuticals, a division of Johnson & Johnson. Links between the use of Xarelto by those who have previously relied on traditional blood thinner medications indicate that an elevated risk of eye and stomach bleeding events may exist.
The U.S. Judicial Panel on Multidistrict Litigation (JPML) recently combined more than 2,800 cases in which plaintiffs alleged that they had been exposed to an elevated risk for catastrophic bleeding events. Judge Eldon Fallon will preside over multidistrict litigation (MDL) 2592 in the Eastern District of Louisiana. In a similar consolidation of lawsuits against the manufacturers of Xarelto, a mass tort program is slated to appear before the Philadelphia Court of Common Pleas and represents more than 500 individual claims.
After considering the increasingly negative opinions directed at the drug, Drs. John C. Hwang and Judy H. Hun decided to conduct an empirical study of patients within their own practice. Their focus encompassed those individuals in their 70s and 80s who had transitioned from a traditional anticoagulant to Xarelto. Reviewing the data, the doctors noted, "In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.” Their findings were published in the June 2015 issue of JAMA Ophthalmology.
In another more expansive and longitudinal study, which was published in the British Medical Journal (BMJ) in April of 2015, more than 46,000 patients who took either traditional blood thinner medication or Xarelto were observed. The researchers noted that those taking Xarelto experienced a twofold increase in the risk of stomach bleeding episodes when compared with those taking warfarin. Taken together, the two studies appear to offer more compelling links between bleeding risks and the new-generation anticoagulant. Hun and Hwang voiced their hope that such research would give pause to doctors considering Xarelto as a treatment option.
http://www.digitaljournal.com/pr/3003292#ixzz4EE2Roo6j
-
Studies Could Substantiate Claims In Xarelto Lawsuit Cases
Jul 11, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com offers insight on recent research that may lend credibility to the claims against Xarelto and its manufacturers—Janssen Pharmaceuticals (a division of Johnson & Johnson) and Bayer AG. The observations of researchers appear to substantiate Xarelto's potential association with eye and gastrointestinal bleeding events, which would aid the case against the new-generation anticoagulant.
The U.S. Judicial Panel on Multidistrict Litigation (JPML) aggregated more than 2,000 federal lawsuits with the common allegation that use of the drug had exposed plaintiffs to an elevated risk of catastrophic bleeding events. The multidistrict litigation (MDL) 2592 will be tried in the Eastern District of Louisiana under the supervision of Judge Eldon Fallon. In a similar group of lawsuits against Xarelto, more than 550 cases were combined to form a mass tort program, which will appear before the Philadelphia Court of Common Pleas.
Drs. Judy H. Hun and John C. Hwang decided to test the negative critique of Xarelto by conducting an empirical analysis of patients within their own practice. Observing those in their 70s and 80s with a history of traditional anticoagulant use who had recently switched to Xarelto, the physicians noted apparent links. They stated, "In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated. As well, they voiced the hope that their study—published in the June 2015 issue of JAMA Ophthalmology—would instill a note of caution in physicians planning to transition patients from traditional blood thinners to Xarelto.
However, the more broadly-based study published in the April 2015 issue of the British Medical Journal (BMJ) may lend even more compelling information to the litigation process. More than 46,000 patients currently taking either traditional anticoagulants or those of the new-generation variety were observed. Within the bounds of their observation, researchers noted that there was an apparent twofold increase in the risk of stomach bleeding on the part of Xarelto patients, as compared with those who took warfarin.
The JPML ordered that any federal lawsuits filed subsequent to the formation of the MDL should be incorporated into the process. As MDL 2592 proceeds toward bellwether trials, plaintiffs are confident that additional lawsuits will continue to be incorporated into the mass litigation.
http://www.digitaljournal.com/pr/3001781#ixzz4EDwE13fj
-
Xarelto Earns Another Dubious Distinction From ISMP: Most Serious Injuries of All Drugs in 2015
Jul 12, 2016 | XareltoLawsuit.com
By Miller Legal LLP
The blood thinner Xarelto (rivaroxaban) has often been labeled by some as a dangerous drug because of the risks of internal bleeding, strokes, blood clots, wound infections and other side effects with which it has been associated. In fact, the Institute for Safe Medication Practices (ISMP), a noted consumer advocacy group, has repeatedly drawn attention to Xarelto risks through their QuarterWatch reports and has even suggested that the risks of Xarelto may outweigh the benefits. Now, Xarelto is again given extra attention in the group’s most recent QuarterWatch report, in which they state that Xarelto was associated with more serious injuries than any other drug they monitored in 2015.
In the recent QuarterWatch report regarding data from the fourth quarter of 2015 and published on June 29, the ISMP states that the FDA received more adverse event reports regarding serious injuries allegedly caused by Xarelto than they did for any other drug they monitor. Here, the ISMP states, “Rivaroxaban (XARELTO), an oral anticoagulant, accounted for the largest number of reported cases of domestic, serious injury among regularly monitored drugs, a total of 10,674 reports, including 1,121 patient deaths and 4,508 injuries requiring hospitalization. The most frequent side effect was hemorrhage, accounting for 8,643 cases.” To compare, the median number of adverse events for the other 1,395 drugs monitored during this quarter was 7, and 25% of the drugs monitored had 4 or fewer adverse events reported.
This is not the first time Xarelto has been singled out by the ISMP. In a QuarterWatch report on the first quarter of 2013 published in May 2014, the ISMP stated that they had noted more adverse reports regarding Xarelto than regarding Pradaxa, another new-generation anticoagulant which had previously received more adverse event reports than any other drug monitored. Here, the group stated that anticoagulants like Xarelto and Pradaxa were found to cause serious bleeding events in roughly 15% of the patients who used them for at least one year.
Xarelto and Pradaxa are both novel oral anticoagulants, a relatively new class of blood thinners marketed as superior alternatives to the previous go-to blood thinner, warfarin (Coumadin). While warfarin patients require regular blood monitoring to ensure that their blood is clotting properly and must also adhere to dietary restrictions, it was initially thought that patients taking Xarelto and related drugs did not need to worry about these inconveniences. In Xarelto lawsuits, now plaintiffs are alleging that they were led to believe through these advertisements that Xarelto was not only more convenient than warfarin, but that it may also be safer and pose a lower risk of a notorious side effect of anticoagulants, internal bleeding. However, the truth is that internal bleeding is a risk with any blood thinner, and that in warfarin patients it may be stopped with a dose of Vitamin K. There is no antidote or reversal agent for Xarelto internal bleeding, and now plaintiffs claim that if they had known this they may not have opted to use the drug.
In their recent report, the ISMP states that direct-to-consumer marketing which focused on the convenience of Xarelto and perhaps downplayed the risks of the drug may be part of the reason for the high rates of Xarelto injury reports. They say, “A major misstep in patient safety occurred with the approval of a new generation of anticoagulants marketed for ease of use rather than improved safety or efficacy.” The group also claims that the “convenient” once-daily dosing of Xarelto may also contribute to serious injuries, when lower doses given twice daily may result in more stable levels of the drug in patient’s systems and thus prevent some internal bleeding episodes and other adverse events.
In addition to internal bleeding, Xarelto patients have also suffered from wound infections, strokes, blood clots (which the drug is designed to prevent), and other dangerous and potentially fatal side effects. Now, thousands of individuals have filed Xarelto lawsuits against drug makers Janssen Pharmaceuticals and Bayer Healthcare, claiming that these pharmaceutical companies failed to properly test Xarelto or to warn of potential risks. If you or someone you love has suffered from or died from side effects associated with the drug Xarelto, you may be entitled to compensation for your damages.
-
Jul 12, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com offers insight on the latest developments in the mass litigation against Xarelto and it's manufacturers—Janssen Pharmaceuticals, a division of Johnson & Johnson, and Bayer AG. Late in 2015, the U.S. Judicial Panel on Multidistrict Litigation agreed to combine 2,800 federally-filed lawsuits against the drug companies on the basis of common allegations. They appointed Judge Eldon Fallon to preside over the MDL in the Eastern District of Louisiana.
In an attempt to clarify and facilitate the process of justice, Fallon has issued case management orders. Plaintiffs and defendants were instructed to select ten cases from the total number of lawsuits filed. These would be joined by twenty cases selected by the court to form a case pool for bellwether trials. From this pool, four cases would be selected and proceed to trial by jury.
The U.S. Food and Drug Administration granted approval to Xarelto in July of 2011. The drug was intended as an anticoagulant for patients with deep vein thrombosis and pulmonary embolism or for those recovering from hip or knee surgeries. Soon after, it was approved as a stroke preventative for individuals with atrial fibrillation. While the drug was initially warmly embraced by the public and medical circles, opinion has since turned sharply against it.
Plaintiffs of both MDL No. 2592 and a mass tort program of 550 individual cases slated to appear before the Philadelphia Court of Common Pleas aver that the drug exposes patients to an elevated risk of catastrophic bleeding events. They claim that this can cause injury requiring extensive medical care and even result in death.
As the plaintiffs of MDL 2592 await trial dates, they are optimistic that additional cases filed in federal courts will continue to be added to their numbers.
http://www.digitaljournal.com/pr/3003587#ixzz4EJOFKOiv
-
CardioBrief: Warfarin Monitoring System Cited in Controversy Withdrawn
Jul 13, 2016 | Larry Husten
By MedPage Today
The Alere INRatio and INRatio2 PT/INR Monitoring System are being pulled from the market.
Alere, the manufacturer of the devices, which are used by people taking warfarin (Coumadin) to monitor their INR, said that the action follows a "collaborative process" with the FDA. The company said it "is working with the FDA to determine the most appropriate timing for product discontinuation and will provide guidance on transitioning patients to an alternate solution to allow them to continue anti-coagulation monitoring in the least disruptive manner possible."
The portable monitoring systems were relatively obscure until last year, when the findings of the pivotal ROCKET AF trial were called into question after it was revealed that the Alere device used to monitor and calibrate warfarin usage in the trial had been defective and the subject of a serious FDA recall.
Since then the FDA, the European Medicines Agency, and the trial investigators have sought to confirm the findings of ROCKET AF, which compared rivaroxaban (Xarelto) with warfarin in patients with atrial fibrillation. Recently the trial investigators published a letter in the New England Journal of Medicine comparing readings from the Alere device with stored blood samples taken during the trial. The trial investigators found that there were potentially important differences between the two methods, but that the main findings of the trial did not appear to have been compromised.
In December 2014, Alere issued the first alert informing users that the devices should not be used by patients with certain medical conditions. Alere said that, at the end of 2015, it submitted software enhancements to the FDA that corrected the earlier problems, but "the FDA notified the company that it believes the company's studies do not adequately demonstrate the effectiveness of the software modification and advised Alere to submit a proposed plan to voluntarily remove the INRatio device from the market."
In February, Abbott agreed to purchase Alere for $5.85 billion. It has since tried to back away from the deal because of a U.S. investigation into Alere's foreign operation, according to a report in Bloomberg.
http://www.medpagetoday.com/cardiology/cardiobrief/59049
-
Vermont Man Dies From Uncontrollable Bleed, Daughter Files Xarelto Lawsuit
Jul 13, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com outlines the details of a new development in Vermont, where a local woman has filed a lawsuit against the manufacturers of the anticoagulant, Xarelto, alleging that the drug caused her father’s uncontrollable bleeding incident and resulting death. The manufacturers of Xarelto are Bayer AG and Janssen Pharmaceuticals, which is a subsidiary of Johnson & Johnson corporation. The lawsuit was filed on July 25th, 2014 in a federal court in Vermont, and was filed under No. 2:14-cv-00158-CR by the victim's daughter on behalf of her father.
Court documents report that the plaintiff’s father was prescribed Xarelto to treat his atrial fibrillation condition, which is a heart condition that often times puts individuals at a greater risk for strokes, or severe blood clots. Certain patients utilize blood thinners to minimize the risk of strokes or blood clots.
The plaintiff’s father had only been taking Xarelto for a brief time before he unexpectedly sustained a head injury, which regrettably caused a brain bleed that doctors could not force to clot. The Vermont man was diagnosed with a parenchymal hemorrhage, which is a severe brain bleed that often leads to strokes, which sadly killed the man after 6 days of doctors’ efforts to stop the bleed.
The plaintiff’s lawsuit alleges that, because of the negligence displayed by manufacturers Janssen Pharmaceuticals, and Bayer AG in initially releasing a drug to consumers without an antidote, consequently led to her father’s sudden death and failing to warn consumers of the potential risks associated with the use of the drug. Over 2,800 federally-filed lawsuits, including this Vermont suit, have been filed and consolidated into MDL No. 2592, which is being overseen in the Eastern District of Louisiana by the Honorable U.S. District Judge Eldon E. Fallon. Furthermore, a mass tort program in Philadelphia, Pennsylvania recently has consolidated an additional 550 Xarelto lawsuits, as more lawsuit cases arise every day.
http://www.digitaljournal.com/pr/3004960#ixzz4EJnLxfAC
-
Almost 6000 Lawsuits Consolidated in Xarelto Litigation
Jul 14, 2016 | LawyersandSettlements.com
By Heidi Turner
New Orleans, LA -- With almost 6,000 Xarelto lawsuits consolidated for pretrial proceedings, and more being regularly filed, plaintiffs await the day that bellwether trials will be heard. Those bellwether cases will set the tone for future Xarelto litigation, and will show both sides what the experts have to say about Xarelto side effects.
According to the Judicial Panel on Multidistrict Litigation, as of June 15, 2016, there were 5,853 lawsuits consolidated for pretrial proceedings in MDL 2592. Those lawsuits allege patients suffered uncontrolled bleeding events leading to serious injury as a result of using Xarelto. Inclusion in the MDL is not a comment on the lawsuits’ merits; rather it is an acknowledgement that the suits share similar questions of fact.
Those questions of fact involve uncontrolled bleeding linked to the use of Xarelto. Because Xarelto is a blood thinner, uncontrolled bleeding is a risk for patients. But patients allege they were not adequately warned about that risk, nor were they warned that there was no antidote to Xarelto. Patients taking warfarin (an older anticoagulant medication) have an antidote in the form of vitamin K. But patients who take Xarelto and suffer uncontrolled bleeding have to wait for the blood thinner to leave their system.That puts patients at risk of serious side effects including possible death, depending on the nature of the bleeding. And patients reportedly don’t have to use the drug for long to suffer a side effect. The Louisiana Record (6/17/16) reports on David and Rebecca Rowell, who filed a lawsuit against the makers of Xarelto alleging negligent misrepresentation because the companies failed to properly design, research, manufacture and test Xarelto.
The Rowells claim David only used Xarelto for 10 days, from June 19-June 29, 2015, but suffered from life-threatening bleeding as a result of the anticoagulant. Xarelto is given to prevent a risk of blood clots, but the risk of uncontrolled bleeding is also serious, as highlighted by a lawsuit filed by Ruth McGowan.
McGowan filed her lawsuit in July 2014, after her father, Thomas Dunkley, died from uncontrolled bleeding linked to the use of Xarelto. As with David Rowell, Thomas Dunkley reportedly only used Xarelto for around 10 days. On July 26, 2012, Dunkley suffered a parenchymal hemorrhage. He died on August 1, 2012.
The Rowell lawsuit is case number 2:16-cv-07281. The McGowan lawsuit is case number 2:14-cv-159.https://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-43-21605.html?utm_expid=3607522-13.Y4u1ixZNSt6o8v_5N8VGVA.0&utm_referrer=https%3A%2F%2Fnews.google.com%2F
-
Study Results Show Support Xarelto Lawsuit Plaintiff Allegations, Linking Drug To Bleeding Episodes
Jul 14, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the results of several recently concluded studies, that seem to support Xarelto lawsuit plaintiff’s allegations linking the anticoagulant to several dangerous, unexpected bleeding episodes. A multitude of Xarelto lawsuit plaintiffs have alleged that the blood-thinning drug can cause serious and even fatal uncontrollable bleeding episodes, which makes these new findings even more important to the rapidly approaching Xarelto bellwether court proceedings.
Xarelto was approved by The U.S. Food and Drug Administration (FDA) in 2011 to treat patients with an increased risk of blood clots or stroke. The blood thinner was intended to be given to those recovering from hip or knee replacement surgeries, and to individuals with deep vein thrombosis or pulmonary embolism. It was also approved for the treatment of those who have the common heart condition, atrial fibrillation, in order to reduce the risk of strokes. Shortly after Xarelto was released to the market, patients began to link the drug to several severely dangerous potential side effects.
After hearing of these potentially life-threatening side effects of Xarelto, doctors Judy Hun and John Hwang decided to take matters into their own hands and conduct a study to investigate the effects of the anticoagulant on their own patients. Throughout their study, the 2 doctors noticed that multiple patients had developed “spontaneous vitreous hemorrhage,” which is a form of eye bleeding while taking Xarelto. After further investigation, Hun and Hwang concluded that risks of eye bleeds are increased for patients who had switched to a Xarelto regimen after previously using a more traditional blood thinner.
Another study has also linked the use of Xarelto with unexpected bleeding episodes. This study was conducted from October 1st of 2010 to March 31st of 2012 and evaluated a large number of people across the U.S. who used the anticoagulants: Xarelto, Pradaxa, or warfarin. After observing a sample of 46,000 patients, including 39,607 warfarin users, 4,907 Pradaxa users, and 1,649 Xarelto users, results concluded that there is “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”
Currently, lawsuits have been filed against Xarelto manufacturers, Bayer AG and Janssen Pharmaceuticals, in over 2,800 cases in federal court. Following MDL No. 2592 in Louisiana, an additional 550 cases were consolidated into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas. The Honorable Judge Eldon E. Fallon has been tasked with the oversight of MDL No. 2592 in the Eastern District of Louisiana.
http://www.digitaljournal.com/pr/3006840#ixzz4EUlI8K9P
-
Jul 14, 2016 | The ProductLawyers.com
By Banville Law
TheProductLawyers.com reports on an update in the on-going Xarelto multidistrict litigation in Louisiana. MDL No. 2592 currently has 2800+ cases that are being overseen by U.S. District Judge Eldon E. Fallon in the Eastern District of Louisiana. The first two bellwether trials will be held on February 6th and March 13th of 2017. In the following months, the remaining two bellwether trials will be heard on April 24th and May 30th respectively.
Shortly after the formation of MDL No. 2592, a mass tort program was created by the Court of Common Pleas in Philadelphia, Pennsylvania consolidating an additional 550 cases. Similar to the MDL in Louisiana, the Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson and Johnson have been named as defendants in all on-going cases.
Common allegations from various plaintiffs include that the anticoagulant places patients at an increased risk for dangerous, uncontrollable bleeding episodes. Xarelto has also been linked to strokes, blood clots, brain hemorrhages, and gastrointestinal bleeding, causing most plaintiffs to claim that Bayer and Janssen failed to properly warn the public of the potential consequences resulting from the drug.
The early 2017 bellwether trials are expected to provide plaintiffs and their lawyers with a more accurate outlook of how jurors and judges will evaluate certain testimonies or evidence in future trials. On June 11, 2016, the presiding judge ordered that the plaintiffs and defendants each to select 20 cases, for a total of 40 suits, to create a bellwether pool, after which, the Louisiana judge will choose 4 trial-ready cases to be heard in the Spring 2017 bellwether trials.
http://www.digitaljournal.com/pr/3006708#ixzz4EUlnzkWj
-
Jul 14, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com recently outlined the sizable similarities between Xarelto and Pradaxa lawsuits, which have provided some hope to Xarelto lawsuit plaintiffs as they await future court dates. Xarelto lawsuit cases are currently still increasing in number, and cases have been consolidated in both Louisiana and Pennsylvania. The U.S. Judicial Panel on Multidistrict Litigation created MDL No. 2592, which was appointed to U.S. District Judge Eldon E. Fallon of Eastern Louisiana, and contains over 2,800 cases.
Louisiana MDL plaintiffs have claimed that in August of 2015, the MDL grew by an estimated 400 cases. Additionally, in Philadelphia, Pennsylvania, another group of cases has been consolidated by the Court of Common Pleas and has since led to the formation of a mass tort program, handling more than 550 cases and pushing the total number of Xarelto lawsuit cases to over 3,500 cases.
All plaintiffs, whether in Pennsylvania or Louisiana have named manufacturers Bayer AG and Johnson and Johnson subdivision: Janssen Pharmaceuticals as defendants, often allegedly claiming negligence by the 2 pharmaceutical giants. Judge Fallon required that 40 bellwether cases be selected by January 11th, 2016, to form a bellwether pool of cases from which the 4 bellwether cases will be chosen.
The 4 final cases will be chosen for bellwether trials in the Spring of 2017, in the hopes of expediting the process of future lawsuits and settlements. One of the most common allegations presented by plaintiffs is that the anticoagulant drug can cause unexpected, uncontrollable bleeding episodes.
Xarelto lawsuit cases are currently displaying striking parallels to blood thinner Pradaxa, which was released to the public in 2010 by manufacturer Boehringer Ingelheim. Similarly to the recent allegations against Xarelto, shortly after Pradaxa was introduced to the market it was named in over 3,500 adverse event reports, which included over 750 fatalities. Eventually, Pradaxa became the topic of over 4,000 lawsuits. Just prior to the scheduled start of the Pradaxa trials, the manufacturer settled all cases and paid $650 million to plaintiffs. Many Xarelto plaintiffs are currently hoping for settlement talks, often citing the Pradaxa settlement as an example of what could be a possibility for them.
http://www.digitaljournal.com/pr/3006560#ixzz4EUmDzq23
-
Jul 14, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on another lawsuit that has been filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals, a division of Johnson & Johnson. The lawsuit was filed against the manufacturers, in relation to Xarelto, which is an anticoagulant drug that has been a popular blood thinner on the market for nearly 5 years. Since hitting the market, thousands of similar lawsuits have been filed nationwide.
The recent complaint in Texas has been filed under case number 1:14-cv-04524. The complaint was originally filed in the Eastern District of New York, before it joined over 2,800 other consolidated cases in Eastern Louisiana under the jurisdiction of the U.S. District Judge Eldon E. Fallon, as directed by the U.S. Judicial Panel on Multidistrict Litigation. This consolidation of cases being overseen in the Eastern District of Louisiana is MDL No. 2592.
The Texas plaintiffs allege that defendants Bayer and Janssen failed to warn patients and medical personnel of the potential risks related to Xarelto. The female plaintiff stated that she was prescribed Xarelto by her doctor, in an attempt to prevent strokes after being diagnosed with atrial fibrillation condition, which is associated with an increased risk of strokes, and severe blood clots. After using Xarelto for 5 months, the female victim suffered from an unexpected, dangerous internal bleed, which she claims has left her with lasting physical and emotional trauma.
Shortly after being released to the public, Xarelto was met with high approval from the public, mainly due to the freedoms it offered versus other blood thinners. However, within the short time, it has been on the market, over 3,400 lawsuits have been filed against the manufacturers of the drug. Common allegations stated by plaintiffs are that the Xarelto can place patients at an increased risk for severe bleeding episodes, and in some cases, plaintiffs allege that the drug can even cause internal and external dangerous bleeds. MDL No. 2592 contains over 2,800 Xarelto lawsuit cases, and the number of cases is expected to continue to rise rapidly. Additionally, the Philadelphia Court of Common Pleas created a mass tort program and consolidated over 550 lawsuit cases.
http://www.digitaljournal.com/pr/3004999#ixzz4EUmVaxvQ
-
Xarelto Lawsuit: In Favor of Victims
Jul 9, 2016 | WeaselReader.org
By Weasel
Modern medical science is a boon for the patients suffering from various ailments. But these drugs, having been made of chemicals, also lead to some side effects, many of which can be of a serious nature. One such drug is Xarelto, an anticoagulant prescribed by physicians to their patients suffering from hypertension and cardiovascular diseases. There is no doubt that Xarelto does its work well and keeps the blood of the user thin to prevent any chances of thrombosis. But it also causes some side effects, the most serious of them being internal bleeding because of injuries. What is baffling to know is the fact that this uncontrolled bleeding can prove to be fatal as there is no known antidote for this bleeding.
While other blood thinning drugs have proved to be harmless, it is Xarelto that seems to be the odd man out. Many individuals have lost their lives after suffering from side effects of xarelto while thousands face lots of miseries even though they survive. Xarelto lawsuit is an attempt to force the manufacturer to pay compensation to these victims of the drug. Janssen Pharmaceuticals is the company that has manufactured this drug while Bayer has marketed it.
http://weaselreader.org/xarelto-lawsuit-in-favor-of-victims/
-
Plaintiffs Oppose Proposed $11.75M Pelvic Mesh Settlement
Jul 11, 2016 | Top Class Actions
By Amanda Antell
Three dozen women are objecting to a proposed $11.75 million pelvic mesh settlement, stating they want proof that the payout would be greater than if the manufacturing company liquidated itself.
Caldera Medical Inc. proposed the pelvic mesh settlement in California federal court, in an attempt to resolve thousands of pelvic mesh lawsuits.
These claims were filed by numerous women who were allegedly injured by the pelvic mesh side effects that the company failed to warn them against.
According to plaintiff attorneys, an independent audit would be necessary to confirm whether or not Caldera Medical was offering the maximum amount possible for the pelvic mesh settlement.
Overview of Pelvic Mesh Settlement
In January 2016, U.S. District Judge Stephen V. Wilson granted preliminary approval to the settlement. This motion was jointly filed by Caldera Medical, the company’s insurance provider, and 23 named plaintiffs representing a potential class of 3,800 women.
Each of these claimants had reportedly suffered pelvic mesh complications, and filed legal action against the company for allegedly opting to omit this information from the mesh product’s safety instructions.
Caldera Medical has denied all of the allegations and argues that an audit is not necessary because the company already produced financial records illustrating the proposed pelvic mesh settlement was the maximum that could be paid.
The financial records the company produced show Caldera Medical is currently not generating profit, and is using its insurance proceeds to finance the pelvic mesh settlement. Furthermore, the company stated there was nothing to suggest that liquidating the company would exceed the settlement amount in any way.
When Judge Wilson questioned how the company was still functioning, Caldera Medical attorneys explained that a substantial portion of shareholders are holding the company up to allow the 30 remaining employees to maintain their jobs.
When Judge Wilson inquired about the company’s CEO salary the attorneys stated they did not know. The annual payroll of the company was approximately $2.3 million, which averages to $70,000 per employee. Judge Wilson asked what other types of claims the company was expecting, since the current pelvic mesh settlement does not have an opt out provision.
The company’s attorneys state that the class is defined as as patients who received Caldera Medical mesh products and suffered pelvic mesh complications as of May 2016. Opponents of the pelvic mesh settlement, however, argued that until the company is audited the question of adequate compensation for the claimants would be in question.
The plaintiff attorneys pointed out financial documents that showed their annual revenue last year was $7.2 million, with just $2.3 million lost to employee salaries.
According to the pelvic mesh settlement administrator, it is currently estimated there are between 3,340 and 3,843 claimants who were allegedly affected by pelvic mesh side effects. This averages to approximately $2,780 per patient, with patients who suffered more severe pelvic mesh complications receiving higher amounts.
The Caldera Medical Pelvic Mesh Settlement pertains to Case No. 2:15-cv-00393, in the U.S. District Court of Central California.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/338889-plaintiffs-oppose-proposed-11-75m-pelvic-mesh-settlement/
-
Eliquis Wrongful Death Lawsuit Says Blood Thinner Unsafe
Jul 11, 2016 | Top Class Actions
By Ashley Milano
Pfizer and Bristol-Myers Squibb are facing an Eliquis wrongful death lawsuit, alleging that their blood thinner Eliquis (also known as apixaban) is dangerous and should not be prescribed.
The surviving spouse of a Mississippi man, Plaintiff Judy B. filed the Eliquis wrongful death lawsuit on June 23 on behalf of her deceased husband, Donald B.
Judy alleges that the manufacturers of the blood thinner medication, Pfizer and Bristol-Myers Squibb, failed to warn patients and physicians of the increased risks of irreversible and fatal internal bleeding when using Eliquis.
According to the Eliquis wrongful death lawsuit, Donald was prescribed Eliquis in June 2015 because of a diagnosis of atrial fibrillation (irregular heartbeat).
Less than three months later, Donald suffered from internal bleeding allegedly a direct result of Eliquis injuries which ultimately led to his death on September 10, 2015.
The Eliquis wrongful death lawsuit claims that Pfizer and Bristol-Myers Squibb knew of the Eliquis side effects and continued to sell it even though they knew the dangerous risks.
What is Eliquis?
Eliquis (apixaban) was developed jointly by Pfizer and Bristol-Myers Squibb and is an anticoagulant, or blood thinner medication, approved by the U.S. Food and Drug Administration (FDA) in 2012.
Originally, Eliquis was approved for stroke prevention in patients who have a heartbeat irregularity known as atrial fibrillation. Use was later expanded to patients at risk for pulmonary embolism or deep vein thrombosis, conditions also caused by blood clots.
Eliquis is in the same family of anticoagulants as Pradaxa and Xarelto. These medications were widely proclaimed to be far superior to the previous blood thinning medication, warfarin (Coumadin), because they reportedly don’t require patient blood monitoring and have fewer dietary restrictions.
Eliquis Injuries: Internal Bleeding
All anticoagulants are designed to reduce the likelihood of dangerous blood clots. However, this also means that it is more difficult for blood to clot in necessary situations.
When a patient develops internal bleeding or hemorrhaging while taking warfarin, the bleeding event can be stopped with a dose of Vitamin K. What the makers of Eliquis were not perhaps forthcoming about is that at this time there is no such reversal agent for Eliquis injuries such as internal bleeding, an Eliquis side effect which may be fatal.
Like all anticoagulants, there is a risk that Eliquis will produce internal bleeding. Since Eliquis is just entering the market, there is no way to know whether Eliquis will cause fewer problems than Pradaxa and Xarelto.
Patients should bear in mind, however, that Eliquis shares the most serious problem associated with the other two drugs: the lack of an antidote that will reverse its anticoagulant effects.
An article in the Cleveland Clinic Journal of Medicine places Eliquis in the same risk category as Pradaxa and Xarelto, noting that doctors have serious difficulty managing the internal bleeding that the three drugs produce.
Eliquis Wrongful Death Lawsuit Information
So far, nearly 1,000 Eliquis patients have suffered major or fatal internal bleeding. Due to the growing use of Eliquis and the potential that the drug’s risks were not disclosed to patients, lawyers anticipate that hundreds of Eliquis patients may eventually come forward to file Eliquis lawsuits.
These Eliquis lawsuits will likely allege that the makers of the drug failed to properly warn users of internal bleeding risks or that no antidote is available for bleeding emergencies. They may also allege that the drug companies hid data about its risks.
If you or your loved one has suffered from Eliquis side effects or even wrongful death due to Eliquis injuires, you may be entitled to substantial compensation.
The Eliquis Wrongful Death Lawsuit is Case No. 1:16-cv-04904, in the U.S. District Court for the Southern District of New York
https://topclassactions.com/lawsuit-settlements/lawsuit-news/339604-eliquis-wrongful-death-lawsuit-says-blood-thinner-unsafe/
-
Xarelto Lawsuit Says Drug Makers Failed to Warn About Bleeding
Jul 14, 2016 | Top Class Actions
By Paul Tassin
A man from Michigan has filed a Xarelto lawsuit blaming the drug’s manufacturers for his episodes of bleeding and need for additional medical care.
Plaintiff Richard P. says he took Xarelto from April 2013 to the following August. He claims he suffered an episode of life-threatening bleeding that itself led to other personal injuries, physical pain and mental anguish.
Treatment for these injuries required hospitalization and additional medical care, he says.
In his Xarelto lawsuit, Richard now argues his bleeding was a direct result of the Xarelto he took and of the failure of the drug’s manufacturers to properly address the side effects of Xarelto.
He alleges defendants Janssen Pharmaceuticals, Bayer Healthcare Pharmaceuticals and their related companies failed to properly evaluate Xarelto’s safety profile.
He also claims the defendants failed to provide adequate warnings and instructions for the use of Xarelto, and he alleges the defendants should have disclosed that Xarelto requires dosage adjustments.
Litigating a Xarelto Lawsuit
Richard’s Xarelto lawsuit is one among thousands of similar claims in an enormous multidistrict litigation, or MDL, that is still proceeding in the U.S. District Court for the Eastern District of Louisiana.
As of May of this year, there are over 5,200 Xarelto lawsuits like Richards pending in the MDL. Attorneys involved in the MDL say they expect even more cases to be filed.
The first four of these cases selected to go to trial, known as “bellwether” cases, have been scheduled to begin between February and April 2017. The four bellwether cases were selected from a pool of 40 assembled in January 2016.
The results from bellwether cases can give the parties an idea about how other, similar trials might play out.
Another group of Xarelto lawsuits is pending in a Pennsylvania state court in Philadelphia. Trials in that group of cases may not begin until after the first trials in the federal MDL.
According to clinical studies and aftermarket reports, an increased likelihood of internal bleeding is one of the side effects of Xarelto.
Compounding that risk is the fact that Xarelto was introduced to the market without any available antidote that could be used to stop its anticoagulant effect in case of emergency.
Without an antidote, Xarelto patients who have experienced internal bleeding have had to simply wait for their body to finish metabolizing the drug. How long that takes is different for different patients.
The same goes for patients who need to undergo surgery. Surgical patients have had to stop taking Xarelto at least 24 hours before surgery to avoid a risk of excessive bleeding during the procedure.
Plaintiffs in the Xarelto lawsuits argue that the unavailability of an antidote puts patients at too great a risk, making the drug a defective product.
They say that manufacturers Janssen and Bayer had no business promoting Xarelto as a safe and effective alternative to the older anticoagulant warfarin, which does have an available and effective antidote.
These plaintiffs argue that Janssen and Bayer knew for years about the increased risk of internal bleeding associated with Xarelto, yet failed to issue an adequate warning that would allow patients and their doctors to make an informed choice about whether or not to use Xarelto.
The Xarelto Lawsuit is Case No. 2:16-cv-03045 filed in the U.S. District Court for the Eastern District of Louisiana.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/339564-xarelto-lawsuit-says-drug-makers-failed-warn-bleeding/
-
Vaginal Mesh Implants Now Under Strict FDA Rules
Jul 14, 2016 | Top Class Actions
By Kim Gale
In January, the FDA issued two final orders to strengthen the data requirements for vaginal mesh implants that are used to treat pelvic organ prolapse.
The orders affect mesh implants that are introduced transvaginally (through the vagina).
What is Pelvic Organ Prolapse?
Pelvic Organ Prolapse (POP) happens when a pelvic organ falls from its normal place in the lower torso and pushes against the walls of the vagina. This condition can occur when the muscles that hold the pelvic organs in place become weak or stretched from childbirth, surgery or aging.
Pelvic organ prolapse can be uncomfortable or painful, and more than one organ can be a problem at the same time. Among the organs that can be affected are:
Bladder
Urethra
Uterus
Small bowel
Rectum
These organs are supported by the same muscles that are often strained during childbirth. When the muscles don’t heal with their previous strength intact, they can’t support the pelvic organs properly.
Vaginal Mesh Implant Issues
To correct pelvic organ prolapse, many women have a procedure to install a vaginal mesh implant that helps support the organs that have dropped from their original place.
Doctors can place the mesh through the abdomen or through the vagina, which is quicker and less invasive. When placed through the vagina, they are called transvaginal mesh implants.
These devices were originally classified as class II medical devices, which means they were of moderate risk. The FDA ordered them reclassified as class III, which includes high-risk devices.
The FDA also ordered that manufacturers of vaginal mesh implants submit a premarket approval (PMA) application to show the safety and effectiveness of the surgical mesh used in transvaginal repair of pelvic organ prolapse.
It is important to note that the new FDA orders do not apply to surgical mesh used for other reasons, such as stress urinary incontinence or abdominal repair of pelvic organ prolapse.
Currently, five companies manufacture vaginal mesh implants, and they will need go through a premarket approval application to prove safety and effectiveness.
The most common problems reported are:
Severe pelvic pain
Pain during intercourse
Infection
Bleeding
Organ perforation
Urinary problems from mesh eroding into surrounding tissue
Reports of severe pelvic pain and organ perforation have been reported with vaginal mesh implants. The new FDA orders to not apply to surgical mesh used for other reasons, such as stress urinary incontinence or abdominal repair of pelvic organ prolapse.
Manufacturers have up to 30 months to submit their premarket approval applications to the FDA.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/339296-vaginal-mesh-implants-now-strict-fda-rules/
-
Xarelto Update: Trials May Begin in 2017
Jul 14, 2016 | FindLaw
By Christopher Coble
For people with irregular heart rhythm, hypertension, or another valvular heart condition, blood thinners can help prevent dangerous and potentially deadly blood clots. But as with any medication, there are risks of side effects.
One such blood thinner, Xarelto, is a popular treatment for adults undergoing hip and knee replacement surgeries. But some patients have suffered from severe internal bleeding after taking Xarelto, sometimes resulting in death. And the lawsuits against the drug’s manufacturer, Janssen Pharmaceuticals, are starting to pile up. Here’s what you need to know about the current litigation.
In Court
The current federal lawsuits, to be heard first in Louisiana, are a combination of 40 cases filed against Janssen and Bayer, claiming the drug manufacturers failed to adequately warn patients that Xarelto could increase the risks for cranial and gastrointestinal bleeding. These “bellwether” cases are slated to begin in early 2017, and could set the tone for future Xarelto lawsuits.
As Judge Eldon E. Fallon of the U.S. District Court for the Eastern District of Louisiana said:
The problem in the past with selecting bellwether cases is that we didn’t drill down on the numbers of cases in order to decide what a good bellwether case is. It was a little bit random. So what we are trying to do now is to pick 40 cases. Hopefully, these 40 cases mimic the census of the entire litigation.
On top of these 40 cases, another 800-plus are scheduled to be processed in Philadelphia’s Complex Litigation Center. (The same court system handling a slew of lawsuits against Janssen based on another of its drugs, Risperdal.)
In Patients
As with all blood thinners, or anticoagulants, Xarelto increases the risk of internal bleeding and may be associated with hemorrhaging in the eye. In addition, patients taking Xarelto were more than twice as likely to experience stomach bleeding than those taking another anticoagulant.
In some cases, internal bleeding has been fatal, as it was with Opal Perkins, who died from a blood transfusion to treat Xarelto-related gastrointestinal bleeding. Hers is one of the many lawsuits heading to trial soon.
If you’ve been suffered from the side effects of Xarelto, you may be entitled to compensation. Contact an experienced personal injury attorney in your area.
http://blogs.findlaw.com/injured/2016/07/xarelto-update-trials-may-begin-in-2017.html
-
What Are the Side Effects of Xarelto?
Jul 15, 2016 | Top Class Actions
By Ashley Milano
Lawsuits against Xarelto’s manufacturers are being filed across the country. The lawsuits allege that side effects of Xarelto caused severe bleeding, injuries and deaths, and that patients and doctors were not adequately warned about the risks of internal bleeding from Xarelto.
Side Effects of Xarelto
Approved in 2011, Xarelto is one of the newest anticoagulants (blood thinners) manufactured.
It has been marketed by Janssen Pharmaceuticals and Bayer and has been widely prescribed to prevent blood clots in patients suffering from atrial fibrillation (arrhythmia of the heart), deep vein thrombosis (blood clots deep within the body), pulmonary embolism (blood clots in the lungs), stroke and in patients who have recently undergone a knee or hip replacement surgery.
It is prescribed as an alternative to warfarin (Coumadin), a blood thinner that began to be used in 1954.
One of the most serious potential side effects of Xarelto is severe internal bleeding that can result in death. The main problem with such bleeding events is that there is no known cure to reverse the type of internal bleeding caused by Xarelto.
Other potential Xarelto problems include thrombosis (blood clots), decreased hemoglobin (a substance that carries oxygen in red blood cells), cerebrovascular accidents (an event that leads to a cerebral hemorrhage), hematoma (a semisolid mass in the blood), peripheral edema (swelling of the lower limbs) and dyspnea (difficulty breathing)
More About Xarelto Problems
Xarelto’s significant risk of severe, and sometimes fatal, internal bleeding has no antidote to reverse its blood thinner side effects.
The original U.S. label approved when the drug was first marketed did not contain a warning regarding the lack of antidote, and only mentioned this important fact in the overdose section.
In 2012, Xarelto’s first full year on the market, a total of 2,081 new Xarelto-associated SAE reports were filed with the FDA. Of those reported blood thinner side effects events, 151 resulted in death, as compared to only 56 deaths associated with warfarin.
Xarelto’s manufacturers promoted the drug as the next generation of blood-thinning drugs to replace warfarin (Coumadin), a long-established safe treatment for preventing stroke and systemic embolism. Warfarin has been in use for 60 years.
However, the clinical studies showed that side effects of Xarelto had a higher rate of bleeding than warfarin without substantial improvement in patient outcome.
In addition, Xarelto’s manufacturers insisted the drug does not require regular blood testing that would determine if patients were at risk of severe bleeding, making it more convenient to prescribe.
However, review of the adverse event reports from Xarelto show that the use of Xarelto without appropriate blood monitoring and dose adjustment can cause major, life-threatening bleeding events.
Xarelto Lawsuit Information
Xarelto lawsuits allege that the manufacturers of Xarelto:
Failed to fully investigate the safety risks of Xarelto
Failed to provide adequate warnings about the true safety risks associated with side effects of Xarelto
Failed to adequately disclose the increased risk of severe bleeding while taking Xarelto
Failed to adequately disclose that there is no antidote to stop bleeding from Xarelto
Over promoted the drug to consumers and healthcare professionals, leading to an explosion in Xarelto sales and putting millions of users at risk
If you or a loved one was hospitalized due to bleeding while taking Xarelto or suffered serious side effects of Xarelto, an experienced Xarelto attorney can offer you a free lawsuit evaluation.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/339389-side-effects-xarelto/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Add recipients
Suggested